Abbott Laboratories (NYSE:ABT – Get Rating) and Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
Insider and Institutional Ownership
72.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 52.2% of Sigilon Therapeutics shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 4.2% of Sigilon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Get Abbott Laboratories alerts:Profitability
This table compares Abbott Laboratories and Sigilon Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abbott Laboratories | 15.88% | 26.09% | 12.82% |
| Sigilon Therapeutics | -336.53% | -87.15% | -41.94% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Abbott Laboratories and Sigilon Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abbott Laboratories | 1 | 3 | 10 | 0 | 2.64 |
| Sigilon Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Abbott Laboratories currently has a consensus price target of $124.67, suggesting a potential upside of 27.38%. Sigilon Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 512.18%. Given Sigilon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sigilon Therapeutics is more favorable than Abbott Laboratories.
Earnings and Valuation
This table compares Abbott Laboratories and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abbott Laboratories | $43.65 billion | 3.90 | $6.93 billion | $3.91 | 25.03 |
| Sigilon Therapeutics | $12.94 million | 2.46 | -$77.31 million | ($1.35) | -0.73 |
Abbott Laboratories has higher revenue and earnings than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Abbott Laboratories has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Sigilon Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Summary
Abbott Laboratories beats Sigilon Therapeutics on 10 of the 14 factors compared between the two stocks.
About Abbott Laboratories
(Get Rating)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1900 and is headquartered in Abbott Park, IL.
About Sigilon Therapeutics
(Get Rating)
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.